Multiple Sclerosis Discovery Forum

Inspiring Connections

Most Viewed

Lymphocytosis as a response biomarker of natalizumab therapeutic efficacy in multiple sclerosis.
Efficacy of exercise intervention programs on cognition in people suffering from multiple sclerosis, stroke and Parkinson's disease: A systematic review and meta-analysis of current evidence.
Simple MRI Metrics Contribute to Optimal Care of the Patient with Multiple Sclerosis.
Simvastatin reduces expression of cytokines interleukin-6, interleukin-8, and monocyte chemoattractant protein-1 in circulating monocytes from hypercholesterolemic patients.
Confounding Psychosis in the Postpartum Period.
Diagnosis and classification of neuromyelitis optica (Devic's Syndrome).
SEMA4D compromises blood-brain barrier, activates microglia, and inhibits remyelination in neurodegenerative disease.
Scan-stratified case-control sampling for modeling blood-brain barrier integrity in multiple sclerosis.
We are about to cure multiple sclerosis in the next 10 years, even though we do not know its cause: Yes.
Magnetic resonance imaging signatures of vascular pathology in multiple sclerosis.
Health beliefs and physical activity behavior in adults with multiple sclerosis.
Induction chemotherapy, extrapleural pneumonectomy, and adjuvant radiotherapy for malignant pleural mesothelioma: experience of Guy's and St Thomas' hospitals.
Acute hypercalcemia following excessive calcium supplementation in a dehydrated patient with progressive multiple sclerosis: vitamin d supplementation is a red herring.
Data supporting Arf6 regulation of Schwann cell differentiation and myelination.
Effect of Vitamin A Supplementation on fatigue and depression in Multiple Sclerosis patients: A Double-Blind Placebo-Controlled Clinical Trial.
Interaction between HLA-DRB1-DQB1 Haplotypes in Sardinian Multiple Sclerosis Population.
Hope for a rare disease: eculizumab in neuromyelitis optica.
Long-term treatment of relapsing-remitting multiple sclerosis with interferon β: how strongly should we encourage patients to adhere to the 'old' therapies?
Safety profile of dalfampridine extended release in multiple sclerosis: 5-year postmarketing experience in the United States.
Mechanisms of action of ACTH in the management of relapsing forms of multiple sclerosis.
Potassium channel KIR4.1-specific antibodies in children with acquired demyelinating CNS disease.
Inhibition of interferon-gamma-mediated microvascular endothelial cell major histocompatibility complex class II gene activation by HMG-CoA reductase inhibitors.
ATX-MS-1467 - Positive Immunological data in Multiple Sclerosis: Final Phase I/IIa data shows safety and tolerability, plus efficacy
Consistency in Administration and Response for the Backward Push and Release Test: A Clinical Assessment of Postural Responses.
Fornix as an imaging marker for episodic memory deficits in healthy aging and in various neurological disorders.

Pages